BCM
ABBV icon

Brooktree Capital Management’s AbbVie ABBV Stock Holding History

Brooktree Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Sell
4,945
-13
-0.3% -$2.8K 0.81% 23
2026
Q1 		$1.08M Hold
4,958
– – 0.86% 25
2025
Q4 		$1.13M Hold
4,958
– – 0.75% 22
2025
Q3 		$1.15M Hold
4,958
– – 0.73% 21
2025
Q2 		$920K Buy
4,958
+3,900
+369% +$725K 0.6% 23
2025
Q1 		$222K Buy
+1,058
New +$206K 0.17% 24
2024
Q4 		– Sell
-1,091
Closed -$215K – 23
2024
Q3 		$215K Buy
+1,091
New +$204K 0.18% 25
2024
Q2 		– Sell
-1,130
Closed -$206K – 24
2024
Q1 		$206K Sell
1,130
-3,517
-76% -$606K 0.16% 24
2023
Q4 		$720K Sell
4,647
-106
-2% -$15.5K 0.58% 24
2023
Q3 		$708K Hold
4,753
– – 0.59% 23
2023
Q2 		$640K Hold
4,753
– – 0.49% 25
2023
Q1 		$757K Sell
4,753
-3,742
-44% -$572K 0.59% 23
2022
Q4 		$1.37M Sell
8,495
-1,050
-11% -$161K 1.13% 19
2022
Q3 		$1.28M Sell
9,545
-211
-2% -$30.3K 1.05% 19
2022
Q2 		$1.49M Sell
9,756
-1,816
-16% -$277K 1.12% 18
2022
Q1 		$1.88M Sell
11,572
-3,383
-23% -$491K 1.22% 21
2021
Q4 		$2.02M Sell
14,955
-1,011
-6% -$119K 1.24% 23
2021
Q3 		$1.72M Sell
15,966
-912
-5% -$104K 1.1% 26
2021
Q2 		$1.9M Sell
16,878
-73
-0.4% -$8.22K 1.22% 26
2021
Q1 		$1.83M Sell
16,951
-3,745
-18% -$401K 1.23% 28
2020
Q4 		$2.22M Sell
20,696
-277
-1% -$26.6K 1.63% 22
2020
Q3 		$1.84M Sell
20,973
-70
-0.3% -$6.59K 1.55% 22
2020
Q2 		$2.07M Buy
21,043
+1,359
+7% +$120K 1.94% 20
2020
Q1 		$1.5M Sell
19,684
-270
-1% -$23K 1.74% 23
2019
Q4 		$1.77M Buy
+19,954
New +$1.66M 1.62% 25

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Brooktree Capital Management's ABBV Position: Q2 2026 in Review

Brooktree Capital Management reduced its AbbVie (ABBV) stake by 0.26% in Q2 2026, selling an estimated $2.8K and leaving 4,945 shares worth $1.24M. The position accounts for 0.81% of the portfolio, ranked #23.

Brooktree Capital Management first reported a position in ABBV in Q4 2019 and has held it in 25 quarters since. The position peaked at $2.22M in Q4 2020. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Brooktree Capital Management held 4,945 shares of AbbVie worth $1.24M as of Q2 2026.
  • Brooktree Capital Management sold 13 AbbVie shares in Q2 2026, an estimated $2.8K.
  • AbbVie made up 0.81% of Brooktree Capital Management's portfolio in Q2 2026, its #23 holding.
  • Brooktree Capital Management first reported a position in AbbVie in Q4 2019 and has held it in 25 quarters since.
  • Brooktree Capital Management's AbbVie position peaked at $2.22M in Q4 2020.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Brooktree Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.